New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 30, 2014
08:42 EDTCVMFrance clears CEL-SCI for patient enrollment in Phase III trial
CEL-SCI announced that the French Agency for the Safety of Health Products has cleared the company to commence patient enrollment for its Phase III Head and Neck Cancer clinical trial of its investigational cancer immunotherapy treatment Multikine in France. In the past three months CEL-SCI has also received governmental clearance to expand its trial into the United Kingdom, Austria, Sri Lanka and Turkey. CEL-SCIís Phase III trial is assessing the companyís investigational immunotherapeutic agent Multikine as a potential first-line treatment for advanced primary head and neck cancer. The Multikine Phase III study is enrolling patients with advanced primary, not yet treated, head and neck cancer. The objective of the study is to demonstrate a statistically significant improvement in overall survival of enrolled patients who are treated with the Multikine treatment regimen plus Standard of Care vs. subjects who are treated with SOC only.
News For CVM From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 22, 2015
09:25 EDTCVMOn The Fly: Pre-market Movers
Subscribe for More Information
09:08 EDTCVMCEL-SCI prices $16M of common stock and warrants at 79c
Subscribe for More Information
08:29 EDTCVMFBR scuttled CEL-SCI offering after 'CEO meddling,' Feuerstein says
FBR scuttled its role in a CEL-SCI (CVM) offering due to "inappropriate CEO meddling," leaving Dawson James to be "brought on to salvage something," according to TheStreet's Adam Feuerstein citing a source. The Fly notes CEL-SCI announced last night a proposed offering of common stock and warrants, with no amount given and Dawson James Securities acting as the sole placement agent on a "best efforts" basis. IsoRay (ISR) tried to raise money yesterday too, Feuerstein reported on Twitter, citing an investor source.
May 21, 2015
18:49 EDTCVMOn The Fly: After Hours Movers
UP AFTER EARNINGS: Hewlett-Packard (HPQ), up 1%. ALSO HIGHER: Autobytel (ABTL), up 14.1% after acquiring Dealix Corporation and Autotegrity from CDK Global (CDK) for $25M and raising fiscal 2015 guidance... StemCells (STEM), up 2.5% after being initiated with a Buy at Cantor... PTC Therapeutics (PTCT), up 2.3% after a Benefit Assessment by Germany's Federal Joint Committee indicated that Translarna provided a benefit for ambulatory patients... CBOE Holdings (CBOE), up 1.6% after raising share repurchase authorization by $100M... Cypress Semiconductor (CY), up 1.2% after being initiated with a Buy at Mizuho. DOWN AFTER EARNINGS: Aeropostale (ARO), down 18.5%... Brocade (BRCD), down 2.1%... Marvell Technology (MRVL), down 2.9% after reporting quarterly results and departure of CFO. ALSO LOWER: Otonomy (OTIC), down 17.7% following report of Phase 2b topline data for OTO-104... Viggle (VGGL), down 18.8% after filing to sell common stock... CEL-SCI (CVM),down 2.7% after announcing a proposed offering of common stock and warrants.
16:35 EDTCVMCEL-SCI announces proposed offering of common stock, warrants, no amount given
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use